NEWS & EVENTS
Taylor Schreiber to present at CD47/SIRPα Summit
Read moreDevelopment and Characterization of SL-172154 (SIRPα-Fc-CD40L) April 17th, 2019 at The Wyndham Beacon Hill – Boston, MA Home
Takeda and Shattuck Labs Announce Collaboration to Explore ARC Fusion Proteins in Immuno-Oncology
Read morePress Release 2017
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Read moreFromm et.al Journal for ImmunoTherapy of Cancer, 18 December 2018
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (PD1-Fc-OX40L), for Cancer Immunotherapy
Read moreSITC 2018
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (SIRPα-Fc-CD40L), for Cancer Immunotherapy
Read moreSITC 2018
Agonist Redirected Checkpoint Platform (ARC); Engineering Bi-Functional Fusion Proteins (TIM3-Fc-OX40L and TIM3-Fc-CD40L), for Cancer Immunotherapy
Read moreSITC 2018